SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http: www.accessdata.fda.gov drugsatfda_docs label 2009 021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance - Little RockNorth Little RockConway metropolitan area - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-06-20 11:12:30 Gastroenterology Exenatide Sitagliptin Glucagon-like peptide-1 Glimepiride Dipeptidyl peptidase-4 inhibitor Glucose tolerance test Anti-diabetic drugs Endocrine system Chemistry		SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance Add to Reading List Source URL: care.diabetesjournals.org Download Document from Source Website File Size: 649,96 KB Share Document on Facebook

	SPECIAL AUTHORIZATION REQUEST DPP-4/SGLT2 INHIBITORS Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – PRESCRIBER INFORMATION DocID: 1pr3h - View Document
	Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES DocID: 1oY1K - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA™ (sitagliptin) Table DocID: 1dJB9 - View Document
	Patient Information JANUVIA™ (jah-NEW-vee-ah) (sitagliptin) Tablets Read the Patient Information that comes with JANUVIA* before you start taking it and each time you get a refill. There may be new information. This le DocID: 1anBo - View Document
	Cardiovascular Pipeline April 6, 2010 DocID: 1amKm - View Document